COMMUNIQUÉS West-GlobeNewswire

AxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference

14/11/2017 - 13:00

ALACHUA, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej [...]

VBL Therapeutics Announces Third Quarter 2017 Financial Results

14/11/2017 - 13:00

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development [...]

Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights

14/11/2017 - 13:00

HAIFA, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI ) (TASE: PSTI ), a leading developer of placenta-based cell therapy products, today reported financial results and corporate [...]

Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195

14/11/2017 - 13:00

– Up to $1.55B in Upfront, Regulatory, and Commercial Milestones – – Loxo Oncology and Bayer to Co-Promote in U.S. with a 50/50 Profit Share; Bayer to Commercialize ROW – – Loxo Oncology to Lead Global Development [...]

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights

14/11/2017 - 13:00

-Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO- -Completion of Initial Public Offering Raising Net Proceeds of $129 million- -Announced Plans to Initiate Two Pivotal Trials of DCC-2618 [...]

UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments

14/11/2017 - 13:00

RA’ANANA, Israel and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ: URGN ), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with [...]

Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer

14/11/2017 - 13:00

Distributor Accutest Now Selling Through Today’s Group THOROFARE, N.J, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health [...]

Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology

14/11/2017 - 13:00

CLARKSVILLE, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Neuronascent, Inc. ( www.neuronascent.com ), a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today announced the European [...]

Transactions in relation to share buyback program

14/11/2017 - 12:58

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

DiamiR Announces Publication of Data on microRNA Biomarkers for Neurodegenerative Diseases in Alzheimer’s Research & Therapy

14/11/2017 - 12:02

MONMOUTH JUNCTION, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today the publication of "Circulating [...]

BioNovelus agrees to Co-Directorship and advisory with Meroe Capital Group Ltd.

14/11/2017 - 12:00

FOR IMMEDIATE RELEASE — Phoenix, Nov. 14, 2017 (GLOBE NEWSWIRE) -- — BioNovelus (ONOV) has today announced the retention of New York-based Meroe Capital Group Ltd. In the structure of the deal, BioNovelus will become a [...]

Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide

14/11/2017 - 08:37

Press Release- No. 11/2017 Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide All 75 subjects dosed with glepaglutide in the clinical trial The [...]

Early close of offering of shares in Orphazyme

14/11/2017 - 08:31

Company announcement Orphazyme A/S No. 3/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 14 November 2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN [...]

Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy

14/11/2017 - 07:16

Presentation of results from the Kisqali ® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer New MONALEESA-2 analyses focused on quality of life, [...]

New data reinforces clinical basis for switching to Sandoz biosimilar medicines

14/11/2017 - 07:11

Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar adalimumab and safety [...]

Targovax to present at upcoming investor conferences

14/11/2017 - 07:01

Oslo, Norway, 14 November 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management will present at [...]

Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 Million of PolyHeal Shares; MediWound Weighing an Appeal

14/11/2017 - 03:33

YAVNE, Israel, Nov. 13, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD ), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound [...]

MolecularMD to Implement Promega’s Microsatellite Instability (MSI) Technology for Immuno-Oncology Applications

14/11/2017 - 02:00

PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MolecularMD announces that it has now become a Preferred Provider of Promega’s Microsatellite Instability (MSI) v1.2 Analysis System. MolecularMD [...]

CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

14/11/2017 - 01:23

Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018 Following a Phase IB Trial [...]